Zim Laboratories Ltd Q3 FY2024 Concall Summary

Key Takeaways

• Revenue rebounded sequentially but FY24 will miss: Total operating income rose 12.2% QoQ to ₹96.3 crore, yet management expects full-year sales to fall 10–15% below the prior year, driven by currency crises in operating countries.
• Differentiated portfolio is now the margin engine: NIP and OTF products together crossed 10% of 9-month revenue at ₹26 crore, and their rising mix is the primary driver of gross margin improvement, even as overall revenue declined YoY.
• Regulatory filings are accelerating into regulated markets: The company filed its first NIP dossier in Spain and Portugal, submitted 17 OTF dossiers globally, and dispatched first consignments of a SAASA product in Europe, marking the start of a multi-year pivot toward higher-value geographies.
• Capacity expansion is underway for the regulated-market opportunity: Management is investing to double overall capacity in two years, with 25–40% enhancement coming from debottlenecking and CapEx, including compliance readiness for ANVISA and other agencies.
• What to watch next quarter: Whether the sequential NIP/OTF growth resumes after Q3’s logistics-driven dip, progress on the two additional EU NIP filings promised for Q4, and any stabilization in currency-affected markets that could narrow the FY24 revenue shortfall.

Differentiated Portfolio: NIP & OTF

• NIP revenue surged 163% YoY in the nine-month period, while OTF grew 31% YoY to ₹9.3 crore; together they contributed over 10% of total operating income for 9MFY24.
• Sequential Q3 dip was logistical, not demand-driven: The QoQ drop in NIP and OTF revenue stemmed from LC issues and supply-related problems, and management expects the average sequential increase to be maintained going forward.
• NIP is the margin differentiator: Management does not separate Pharma and Nutra for margin analysis; it views NIP and ODS together as the businesses whose rising performance naturally lifts overall margins, and this effect is already visible even in markets like India.
• Portfolio economics rely on a few winners: Management expects that 20% of NIP products will generate 80% of the business, more than compensating for all development expenses across the entire portfolio.
• OTF adoption in India is a slow build: The dosage form carries a price premium over tablets and capsules; some partners position it at an extreme premium and find buyers, but broader acceptance of the unfamiliar physical presentation will take time.

Anwar Daud: "We are not thinking of Nutra or Pharma. We are thinking of NIP, and there are certain NIPs which are Nutra as well, and there are certain NIPs which are Pharma. So, NIP and ODS business together, when their performance increases, the margins naturally increase."

Regulated Market Entry & Filings

• First NIP dossier filed in Europe: One innovative NIP product dossier was completed and filed in Spain and Portugal during the quarter, with guidance for two more EU NIP filings in Q4.
• OTF dossier activity is broadening: ZIM and its partners submitted 17 dossiers in total; 12 under ZIM brand names, plus 5 partner OTS dossiers covering Ondansetron in Brazil, Tadalafil in Indonesia, and Rizatriptan in Austria.
• First commercial dispatches to Europe have begun: A SAASA product shipped its first consignments and received new orders; Sildenafil shipped a trial order and already has a repeat order in hand.
• Two NIP products filed in Europe address a specific patient need: Tamsulosin and Dutasteride use liquid-in-pellets technology to produce capsules significantly smaller than the originator product, solving a swallowing difficulty that particularly troubles prostate patients at night.
• Pancreatin filing leverages a low-temperature pellet technology: The enzyme product uses a process for making pellets out of Pancrelipase APIs at low temperature, a capability held by very few players in the market.
• Revenue from regulated markets is a FY25 story: Rollout in Europe and other regulated markets is expected to start reflecting in sales numbers from FY25, with the post-filing Marketing Authorization timeline averaging 1.5 to 2 years.

Anwar Daud: "The large size makes swallowing difficult of the original product. And more water is required to swallow. And if you have more water, then people with prostrate have a lot of problem during the night. So, we feel that we are giving a product with an advantage."

Revenue Headwinds & Recovery

• Currency crises drove the YoY revenue decline: Despite sequential improvement from Q1 through Q3, operating-country currency problems caused a postponement of revenue; management now sees those problems easing, though full recovery will not come in the remaining two months of FY24.
• A single large Nutra order did not repeat: One multi-product Nutra order worth approximately ₹20 crore was lost because the buyer, though not under sanctions, could not access currency; when currency is scarce, countries prioritize pharmaceutical over nutraceutical purchases.
• MENA region sales were down substantially: Currency issues hit the region hard, but the narrowing gap between quarters suggests the problem is easing, and management is adjusting its geographical mix in response.
• India domestic business is a bright spot: Growth was strong for the nine months, partly driven by significant state government orders for Nutraceutical products; management expects 15–20% growth to continue as it explores NIP opportunities in the domestic market.
• Red Sea disruption had limited direct impact: Most business is shipped by air or on an FOB basis, so the crisis did not directly affect operations, though it could indirectly slow the easing of currency pressures.

Anwar Daud: "It doesn't look like that. I feel at this moment we are going to fall short of last year by 10% to 15%."

Capacity & CapEx

• Capacity is set to double in two years: Management guided that overall capacity will double, with 25–40% enhancement coming in the next couple of years across PFI, Nutraceutical, and finished formulation.
• A 40% output increase from debottlenecking is achievable: This near-term gain comes from debottlenecking and capacity addition already underway.
• CapEx is tied to regulatory compliance for new markets: Much of the current investment is directed toward compliance for ANVISA and other agencies, driven by agreements signed in Brazil, Mexico, and other South American markets; an inspection is expected in the latter part of this year.
• Near-term CapEx is quantified; FY25 is not: Another ₹25 crore of CapEx is expected in the next quarter, but management declined to provide a figure for the next financial year, saying the decision will be taken post-audit.

Margins & Profitability

• Gross margin improved despite the revenue decline: Both Pharma and Nutra segments delivered good, consistent margins that are improving, with the NIP and ODS mix shift as the primary driver.
• Government business carries healthy margins: Margins on state government Nutraceutical orders are comparable to, and in some cases better than, current overall margins; receivables are collected within 60–90 days post-shipment per tender terms.
• R&D intensity remains high at 9.6% of total operating income, a level management intends to maintain or improve in line with the strategy of filing in regulated markets and expanding the footprint.
• EBITDA margin target is conditional on macro stability: Management aspires to a 15–17% EBITDA margin if everything goes well and the economy stabilizes, a qualification that ties the target to the same currency and demand uncertainties that drove the FY24 shortfall.

Anwar Daud: "15% is what we -- EBITDA is what we feel we can deliver if everything goes well. ... With the qualification: 15% to 17%. ... With the qualification, with the provisional, then everything goes well. We do well in the economy also; everything stabilizes."

Business Model & Strategic Positioning

• Zim is a formulation out-licensing company, not a contract manufacturer: It does not manufacture APIs and does not do contract manufacturing; its model is to develop differentiated dosage forms and out-license them to partners.
• Out-licensing fees are a growing, gradual revenue stream: The company is already receiving such fees and expects gradual growth as more agreements are signed alongside the accelerating filing cadence.
• The product pipeline spans multiple technology platforms: Management declined to name specific products under development but confirmed activity across almost every technology platform in its portfolio.
• No US market exposure today: The company is not in the US market; its differentiated products are not para IV or first-to-file because those would require clinical trials, a path Zim is not currently pursuing.
• Rupee trade is under exploration: Management is discussing the feasibility of rupee-denominated trade with its lead banker as a potential hedge against the dollar-currency crises that have disrupted revenue; once a bank channel is established, the company would prefer it.

Guidance & Commitments

Key Metrics